Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly

2000107 citationsJournal Article

Authors

Philippe Chanson

Viktor Boerlin · Novartis (Switzerland)

Christiane Ajzenberg · Hôpital Lariboisière

Y. Bachelot · Université Grenoble Alpes

Pedro J. Benito · Hospital Universitario Reina Sofía

J. Bringer · Hôpital Lapeyronie

Philippe Caron · Centre Hospitalier Universitaire de Toulouse

Abstract

Octreotide LAR 20 mg administered once monthly was more effective than lanreotide SR 30 mg administered 2 or 3 times monthly in reducing GH and IGF-I in patients with acromegaly.

Topics & Keywords

Pituitary Gland Disorders and Treatments Growth Hormone and Insulin-like Growth Factors Neuroendocrine Tumor Research Advances

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Clinical Endocrinology

Volume 53, Issue 5, pp. 577-586

DOI: 10.1046/j.1365-2265.2000.01134.x

Field-Weighted Citation Impact: 6.12